Alnylam Pharmaceuticals Inc
NASDAQ:
ALNY
-
Alnylam Pharmaceuticals Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 514
-
Executives
- Michael Bonney
- Barry Greene
- John Maraganore
- Manmeet Soni
- Yvonne Greenstreet
- Akshay Vaishnaw
- Laurie Keating
- Pushkal Garg
- Theresa Heggie
- Peter Smith
-
Company address
- 300 Third Street, 3rd Floor
- Cambridge, MA 02142
- United States of America
- 1-617-551-8200
-
Investor Relation Site
Link
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals Inc: Slide deck
- ALNY - Q2 Investor Presentation 9 Aug 2017: Slides deck
- ALNY - Q1 Investor Presentation 5 May 2017: Slides deck
- ALNY - Q4 Investor Presentation 8 Feb 2017: Slides deck
- ALNY - J. P. Morgan Conference Presentation 9 Jan 2017: Slides deck
- ALNY - Q3 Investor Presentation 2 Nov 2016: Slides deck